The post Alto Neuroscience stock rises as firm secures $120M to advance depression drug appeared on BitcoinEthereumNews.com. Alto Neuroscience, a clinical-stageThe post Alto Neuroscience stock rises as firm secures $120M to advance depression drug appeared on BitcoinEthereumNews.com. Alto Neuroscience, a clinical-stage

Alto Neuroscience stock rises as firm secures $120M to advance depression drug

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Alto Neuroscience, a clinical-stage biopharmaceutical company focused on neuropsychiatric disorders, has secured $120 million from institutional and accredited investors to advance ALTO-207, a fixed-dose combination targeting treatment-resistant depression.

ALTO-207 is a novel therapy for treatment-resistant depression that pairs pramipexole, a dopamine receptor agonist, with ondansetron. The combination is designed to enhance antidepressant effects in patients who have not responded to standard treatments.

According to a Monday statement, the financing, led by Commodore Capital, will enable Phase 2b and Phase 3 clinical trials and potentially support a New Drug Application submission if the studies are successful.

The round also drew participation from Dellora Investments, Driehaus Capital Management, Perceptive Advisors, Spruce Street Capital, Venrock Healthcare Capital Partners, Vestal Point Capital, and other institutional investors.

The PIPE includes common stock and pre-funded warrants, with the transaction expected to close tomorrow.

Alto Neuroscience reports 2025 loss as depression drug trials advance

Alto Neuroscience reported its full-year 2025 results and pipeline progress, saying its $177 million cash balance is expected to fund operations into 2028 and support multiple upcoming clinical milestones. The company highlighted advances across its precision psychiatry programs, including the acquisition of ALTO-207.

Alto plans Phase 2b testing in the first half of 2026, followed by a Phase 3 study in early 2027.

The company also expects topline data around the end of the first quarter of 2026 from a Phase 2 proof-of-concept trial of ALTO-101 for cognitive impairment associated with schizophrenia.

For 2025, Alto reported research and development expenses of over $45 million and general and administrative expenses of $20.7 million. The company posted a net loss of around $63 million for the year.

Alto, which trades on the New York Stock Exchange under the ticker ANRO, saw its stock surge around 7% in premarket trading on Monday, per Yahoo Finance.

Disclosure: This article was edited by Vivian Nguyen. For more information on how we create and review content, see our Editorial Policy.

Source: https://cryptobriefing.com/alto-neuroscience-funding-depression-therapy/

Market Opportunity
Notcoin Logo
Notcoin Price(NOT)
$0.0003822
$0.0003822$0.0003822
-0.57%
USD
Notcoin (NOT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin lays out new Ethereum roadmap at EDCON

Vitalik Buterin lays out new Ethereum roadmap at EDCON

The post Vitalik Buterin lays out new Ethereum roadmap at EDCON appeared on BitcoinEthereumNews.com. At EDCON 2025 in Osaka, Ethereum co-founder Vitalik Buterin delivered fresh details of Ethereum’s technical roadmap, delineating both short-term scaling goals and longer-term protocol transformations. The immediate priority, according to slides from the presentation, is scaling at the L1 level by raising the gas limit while maintaining decentralization. Tools such as block-level access lists, ZK-EVMs, gas repricing, and slot optimization were highlighted as means to improve throughput and efficiency. A central theme of the presentation was privacy, divided into protections for on-chain “writes” (transactions, voting, DeFi operations) and “reads” (retrieving blockchain state). Write privacy could be achieved through client-side zero-knowledge proofs, encrypted voting, and mixnet-based transaction relays. Read privacy efforts include trusted execution environments, private information retrieval techniques, dummy queries to obscure access patterns, and partial state nodes that reveal only necessary data. These measures aim to reduce information leakage across both ends of user interaction. In the medium term, Ethereum’s focus shifts to cross-Layer-2 interoperability. Vitalik described trustless L2 asset transfers, proof aggregation, and faster settlement mechanisms as key milestones toward a seamless rollup ecosystem. Faster slots and stronger finality, supported by techniques like erasure coding and three-stage finalization (3SF), are also in scope to enhance responsiveness and security. The roadmap also includes Stage 2 rollup advancements to strengthen verification efficiency, alongside a call for broader community participation to help build and maintain these improvements. The long-term “Lean Ethereum” blueprint emphasizes security, simplicity and optimization, with ambitions for quantum-resistant cryptography, formal verification of the protocol, and adoption of ideal primitives for hashing, signatures, and zero-knowledge proofs. Buterin stressed that these improvements are not just for scalability but to make Ethereum a stable, trustworthy foundation for the broader decentralized ecosystem. This is a developing story. This article was generated with the assistance of AI and reviewed by editor Jeffrey Albus before publication.…
Share
BitcoinEthereumNews2025/09/18 03:22
WADESK Just Dropped the Ultimate WASender Free Tool for Marketers

WADESK Just Dropped the Ultimate WASender Free Tool for Marketers

Marketing budgets are tight these days. If you are like most small business owners or digital marketers, you are constantly juggling five different expensive subscriptions
Share
Techbullion2026/03/24 18:46
The old and weak president is losing — because he’s old and weak

The old and weak president is losing — because he’s old and weak

I was surprised. Though Donald Trump is the weakest president of my lifetime, in terms of principle and character, I didn't think he would set himself up to prove
Share
Alternet2026/03/24 19:25